Back to User profile » Professor Mario Cazzola
Papers published by Professor Mario Cazzola:
Clinically Important Deterioration (CID) and Ageing in COPD: A Systematic Review and Meta-Regression Analysis According to PRISMA Statement
Manzetti GM, Ora J, Sepiacci A, Cazzola M, Rogliani P, Calzetta L
International Journal of Chronic Obstructive Pulmonary Disease 2023, 18:2225-2243
Published Date: 10 October 2023
Can Treatable Traits Be the Approach to Addressing the Complexity and Heterogeneity of COPD?
Cazzola M, Rogliani P, Blasi F
International Journal of Chronic Obstructive Pulmonary Disease 2023, 18:1959-1964
Published Date: 8 September 2023
Novel Anti-Inflammatory Approaches to COPD
Cazzola M, Hanania NA, Page CP, Matera MG
International Journal of Chronic Obstructive Pulmonary Disease 2023, 18:1333-1352
Published Date: 29 June 2023
The Effect of Maintenance Treatment with Erdosteine on Exacerbation Treatment and Health Status in Patients with COPD: A Post-Hoc Analysis of the RESTORE Dataset [Corrigendum]
Calverley PMA, Papi A, Page C, Rogliani P, Dal Negro RW, Cazzola M, Cicero AF, Wedzicha JA
International Journal of Chronic Obstructive Pulmonary Disease 2022, 17:2451-2452
Published Date: 3 October 2022
The Effect of Maintenance Treatment with Erdosteine on Exacerbation Treatment and Health Status in Patients with COPD: A Post-Hoc Analysis of the RESTORE Dataset
Calverley PMA, Papi A, Page C, Rogliani P, Dal Negro RW, Cazzola M, Cicero AF, Wedzicha JA
International Journal of Chronic Obstructive Pulmonary Disease 2022, 17:1909-1920
Published Date: 22 August 2022
Potential Drawbacks of ICS/LABA/LAMA Triple Fixed-Dose Combination Therapy in the Treatment of Asthma: A Quantitative Synthesis of Safety Profile
Rogliani P, Cavalli F, Chetta A, Cazzola M, Calzetta L
Journal of Asthma and Allergy 2022, 15:565-577
Published Date: 6 May 2022
Beyond Dual Bronchodilation – Triple Therapy, When and Why
Cazzola M, Rogliani P, Laitano R, Calzetta L, Matera MG
International Journal of Chronic Obstructive Pulmonary Disease 2022, 17:165-180
Published Date: 14 January 2022
An Overview of the Safety and Efficacy of Monoclonal Antibodies for the Chronic Obstructive Pulmonary Disease
Cazzola M, Ora J, Cavalli F, Rogliani P, Matera MG
Biologics: Targets and Therapy 2021, 15:363-374
Published Date: 27 August 2021
New Avenues for Phosphodiesterase Inhibitors in Asthma
Matera MG, Ora J, Cavalli F, Rogliani P, Cazzola M
Journal of Experimental Pharmacology 2021, 13:291-302
Published Date: 15 March 2021
Long-Acting Muscarinic Antagonists Under Investigational to Treat Chronic Obstructive Pulmonary Disease
Ora J, Coppola A, Cazzola M, Calzetta L, Rogliani P
Journal of Experimental Pharmacology 2020, 12:559-574
Published Date: 8 December 2020
Experimental Glucocorticoid Receptor Agonists for the Treatment of Asthma: A Systematic Review
Rogliani P, Ritondo BL, Puxeddu E, Pane G, Cazzola M, Calzetta L
Journal of Experimental Pharmacology 2020, 12:233-253
Published Date: 6 August 2020
Pharmacogenomic Response of Inhaled Corticosteroids for the Treatment of Asthma: Considerations for Therapy
Cazzola M, Rogliani P, Calzetta L, Matera MG
Pharmacogenomics and Personalized Medicine 2020, 13:261-271
Published Date: 4 August 2020
Effect of Erdosteine on COPD Exacerbations in COPD Patients with Moderate Airflow Limitation
Calverley PMA, Page C, Dal Negro RW, Fontana G, Cazzola M, Cicero AF, Pozzi E, Wedzicha JA
International Journal of Chronic Obstructive Pulmonary Disease 2019, 14:2733-2744
Published Date: 2 December 2019
The impact of dual bronchodilation on cardiovascular serious adverse events and mortality in COPD: a quantitative synthesis [Corrigendum]
Rogliani P, Matera MG, Ora J, Cazzola M, Calzetta L
International Journal of Chronic Obstructive Pulmonary Disease 2018, 13:3597-3598
Published Date: 31 October 2018
LABA/LAMA fixed-dose combinations in patients with COPD: a systematic review
Rogliani P, Calzetta L, Braido F, Cazzola M, Clini E, Pelaia G, Rossi A, Scichilone N, Di Marco F
International Journal of Chronic Obstructive Pulmonary Disease 2018, 13:3115-3130
Published Date: 4 October 2018
New developments in optimizing bronchodilator treatment of COPD: a focus on glycopyrrolate/formoterol combination formulated by co-suspension delivery technology
D'Urzo AD, Cazzola M, Hanania NA, Buhl R, Maleki-Yazdi MR
International Journal of Chronic Obstructive Pulmonary Disease 2018, 13:2805-2819
Published Date: 7 September 2018
The impact of dual bronchodilation on cardiovascular serious adverse events and mortality in COPD: a quantitative synthesis
Rogliani P, Matera MG, Ora J, Cazzola M, Calzetta L
International Journal of Chronic Obstructive Pulmonary Disease 2017, 12:3469-3485
Published Date: 5 December 2017
Doxofylline is not just another theophylline!
Matera MG, Page C, Cazzola M
International Journal of Chronic Obstructive Pulmonary Disease 2017, 12:3487-3493
Published Date: 5 December 2017
Acute exacerbations of COPD: risk factors for failure and relapse
Mantero M, Rogliani P, Di Pasquale M, Polverino E, Crisafulli E, Guerrero M, Gramegna A, Cazzola M, Blasi F
International Journal of Chronic Obstructive Pulmonary Disease 2017, 12:2687-2693
Published Date: 8 September 2017
Airflow obstruction: is it asthma or is it COPD?
Rogliani P, Ora J, Puxeddu E, Cazzola M
International Journal of Chronic Obstructive Pulmonary Disease 2016, 11:3007-3013
Published Date: 30 November 2016
COPD: the patient perspective
Jones PW, Watz H, Wouters EFM, Cazzola M
International Journal of Chronic Obstructive Pulmonary Disease 2016, 11:13-20
Published Date: 19 February 2016
Specific role of combination aclidinium: formoterol in the treatment of chronic obstructive pulmonary disease
Matera MG, Sanduzzi A, Cazzola M
International Journal of Chronic Obstructive Pulmonary Disease 2016, 11:73-79
Published Date: 5 January 2016
Differential pharmacology and clinical utility of long-acting bronchodilators in COPD – focus on olodaterol
Matera MG, Ora J, Cazzola M
Therapeutics and Clinical Risk Management 2015, 11:1805-1811
Published Date: 4 December 2015
Clinical role of dual bronchodilation with an indacaterol–glycopyrronium combination in the management of COPD: its impact on patient-related outcomes and quality of life
Rossi A, Zanardi E, Poletti V, Cazzola M
International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:1383-1392
Published Date: 23 July 2015
A review of the most common patient-reported outcomes in COPD – revisiting current knowledge and estimating future challenges
Cazzola M, Hanania NA, MacNee W, Rüdell K, Hackford C, Tamimi N
International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:725-738
Published Date: 7 April 2015
The clinical use of regenerative therapy in COPD
Lipsi R, Rogliani P, Calzetta L, Segreti A, Cazzola M
International Journal of Chronic Obstructive Pulmonary Disease 2014, 9:1389-1396
Published Date: 12 December 2014
New developments in the combination treatment of COPD: focus on umeclidinium/vilanterol
Cazzola M, Segreti A, Matera MG
Drug Design, Development and Therapy 2013, 7:1201-1208
Published Date: 10 October 2013